Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Rose as Much as 7.9% Today

By Eric Volkman - Feb 9, 2021 at 7:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The approval process for its top drug is starting in two major Asian markets.

What happened

Amarin (AMRN 5.15%) spiked nearly 8% on Tuesday before falling to earth and landing essentially flat over Monday's close. The day's moves followed a seemingly encouraging development for the only drug the company has on the market.

So what

Amarin announced that the regulatory approval process for Vascepa has started in China and Hong Kong.

On the mainland, the Chinese National Medical Products Administration has accepted a new drug application for the medicine. The Hong Kong Department of Health is separately evaluating it based on current approvals in the U.S. and Canada. Amarin's partner Edding has filed both submissions.

Amarin expects a decision near the end of this year from authorities in both mainland China and Hong Kong.

A medical professional using a microscope.

Image source: Getty Images.

It feels that decision will be in its favor. In Amarin's press release heralding the news, Edding Chief Medical Officer James He said, "Prevention and treatment of cardiovascular disease (CVD) is one of the major initiatives promoted by Health China 2030." Health China 2030 is a broad program to improve the massive Asian country's overall healthcare.

"However, few new [cardiovascular disease] medications other than statins were launched in the market during the past several decades," He added.

Now what

Perhaps the initial enthusiasm over this news was tempered by the sobering realization that Amarin's current fortunes depend heavily on Vascepa. I don't think investors should be discouraged. The drug is still a potential global blockbuster despite recent legal setbacks in the U.S.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.43 (5.15%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.